10/19/2004

An FDA deputy commissioner said the agency has not yet decided if the problems that led to withdrawal of Merck's Vioxx means the agency also should consider whether similar drugs are a concern. "We don't have any definitive evidence" the heart-risk problem that affected the Vioxx arthritis drug also is involved in other drugs in the Cox-2 class, Janet Woodcock said at a conference of arthritis specialists.

Related Summaries